Developer docs
API playgroundTry for free, no card

Search company profiles

QuVa Pharma

Full company profile

uuid0000qsg

Namestring
QuVa Pharma
Legal namestring
QuVa Pharma, Inc.
Websiteurl
quvapharma.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

QuVa Pharma is a privately held, FDA-registered 503B outsourcing facility founded in 2015 and headquartered in Sugar Land, Texas. The company manufactures compounded and ready-to-administer sterile injectable medications for hospital pharmacies across all 50 U.S. states, serving over 3,000 hospitals through direct enterprise sales and national group purchasing agreements — most notably with Premier, Inc. Its core portfolio includes low-dose fentanyl syringes, enhanced tamper-evident CADD cassettes, del Nido cardioplegia solution, and a broader ready-to-administer injectable line supported by forward distribution centers and remote direct distribution capabilities.

The company's go-to-market combines direct enterprise field sales to hospital pharmacy leadership with GPO channel partnerships that provide pre-negotiated pricing for member hospitals. In July 2024, QuVa acquired LogicStream Health and rebranded it as Quva BrightStream, adding an AI-powered clinical data and analytics platform comprising six modules — Shortage Navigator, Diversion Surveillance, Supply Advisor, Script Revenue Capture, Contracts Value Maximizer, and Clinical Process Optimizer — that process data from over 350 health-system data sets to deliver predictive shortage management, controlled-substance monitoring, inventory optimization, and revenue retention analytics.

QuVa is backed by Bain Capital (including its January 2024 $15 million equity investment) and previously financed through a $275 million senior debt facility led by Goldman Sachs and Owl Rock in 2021. The business model is dual-track: product revenue from sterile injectable compounding sold through enterprise and GPO channels, plus an emerging SaaS analytics revenue stream through BrightStream that is now embedded into the same Premier GPO procurement vehicle.

Short descriptiontext

QuVa Pharma is an FDA-registered 503B outsourcing facility that manufactures compounded, ready-to-administer sterile injectable medications for over 3,000 U.S. hospitals, complemented by its BrightStream AI-powered pharmacy analytics platform acquired in 2024.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersSugar Land, United States
HQ citystring
Sugar Land
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
503B sterile compounding, ready-to-administer injectables, hospital pharmacy analytics, drug diversion surveillance, outsourced pharmaceutical manufacturing
Industry3 codes
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLACAKAI
Medication Inventory, Procurement & Supply Chain (Pharmacy)
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLAIAJAD
Hospital & Health-System Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
503B Sterile Injectable Compounding
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1503B Sterile Compounding Services
TypeSubscription Recurring
Description

FDA-registered 503B outsourcing services providing compounded sterile injectable medications to hospitals. Revenue generated through product sales and service agreements with health systems.

onequva.com
2AI & Data Analytics Solutions (BrightStream)
TypeSubscription Recurring
Description

SaaS-based analytics and software solutions for health-system pharmacy performance improvement, including drug diversion surveillance, shortage management, and revenue optimization.

onequva.com
3Ready-to-Administer Portfolio
TypeTransaction Fee
Description

Pre-packaged, ready-to-administer sterile injectable medications that reduce medication errors and improve pharmacy efficiency.

onequva.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Quva BrightStream
Description

AI-powered analytics and data insights platform for health-system pharmacy, offering solutions including shortage navigator, diversion surveillance, supply advisor, script revenue capture, contracts value maximizer, and clinical process optimizer. Formerly known as LogicStream Health.

onequva.com
+2 more records
Core offering1 text field

QuVa Pharma is an FDA-registered 503B outsourcing facility that manufactures and distributes compounded, ready-to-administer sterile injectable medications to over 3,000 U.S. hospitals across all 50 states. Through its Quva BrightStream platform (acquired LogicStream Health in July 2024), the company also delivers AI-powered analytics solutions, including drug diversion surveillance, shortage management, supply optimization, and revenue capture for health-system pharmacies. The combined offering pairs physical pharmaceutical manufacturing with data-driven pharmacy intelligence.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Serves over 3,000 U.S. hospitals
+1 more record
Product overview1 text field

QuVa Pharma operates as a dual-platform company offering pharmaceutical manufacturing and AI-powered analytics solutions. The core QuVa Pharma platform provides FDA-registered 503B sterile injectable compounding services, delivering ready-to-administer medications to over 3,000 U.S. hospitals across all 50 states. Complementing this is the Quva BrightStream platform (acquired LogicStream Health in July 2024), which offers six AI-powered analytics modules including Shortage Navigator, Diversion Surveillance, Supply Advisor, Script Revenue Capture, Contracts Value Maximizer, and Clinical Process Optimizer. Together, these platforms enable health-system pharmacies to access both essential sterile medications and data-driven insights from over 350 data sets to improve operational performance and patient outcomes.

Product and service7 records
1503B Sterile Compounding Services
Category503B Sterile Compounding
Description

FDA-registered 503B outsourcing services providing essential, compounded, ready-to-administer sterile injectable medicines to over 3,000 U.S. hospitals across all 50 states, with industry-first remote direct distribution capabilities and state-of-the-art production facilities.

2Ready-to-Administer Portfolio
Category503B Sterile Compounding
Description

Pre-made sterile injectable medications ready for direct patient administration, designed to reduce medication errors and improve pharmacy efficiency in hospital settings.

3New 503B Product Development
Category503B Sterile Compounding
Description

Custom sterile injectable product development services for new 503B compounded medications to address unmet hospital needs.

4del Nido Cardioplegia Solution
CategoryReady-to-Administer Sterile Injectables
Description

Sterile cardioplegia solution designed for cardiac surgery, manufactured and distributed as a ready-to-administer compounded sterile injectable.

5FentaNYL (Low Dose Fentanyl Syringe)
CategoryReady-to-Administer Sterile Injectables
Description

Preservative-free sterile injectable fentanyl syringe featuring room temperature storage and a 90-day Beyond Use Date (BUD).

6CADD Cassettes
CategoryReady-to-Administer Sterile Injectables
Description

Sterile injectable cassettes with enhanced tamper-evident cap and packaging to support prevention of leakage and diversion in hospital pharmacy settings.

7Quva BrightStream Analytics Platform
CategoryPharmacy Analytics Software
Description

AI-powered analytics and data insights platform (formerly LogicStream Health) that transforms fragmented health-system data from over 350 data sets into actionable intelligence to improve pharmacy performance and patient outcomes, including drug diversion surveillance, shortage management, and supply optimization.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-01
Description

QuVa Pharma secured a national group purchasing agreement with Premier, Inc. for its Drug Diversion Software Solutions, effective May 1, 2026. This agreement enhances Premier members' access to QuVa's BrightStream solutions, which help safeguard controlled substances and improve pharmacy compliance and oversight.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-01
Description

QuVa Pharma was awarded a national group purchasing agreement for outsourced compounded preparations with Premier, Inc., effective November 1, 2025. This agreement allows Premier members to benefit from pre-negotiated pricing and supports QuVa's role as a provider of sterile injectable compounding services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-25
Description

QuVa Pharma completed the acquisition of LogicStream Health in July 2024, creating an integrated healthcare platform combining pharmaceutical distribution and AI-powered clinical data solutions. LogicStream Health has been rebranded as BrightStream and provides predictive analytics, drug diversion surveillance, and other pharmacy optimization solutions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Owned by B. Braun, CAPS is one of the largest 503B sterile compounding outsourcing networks in the U.S., directly competing with QuVa across the same hospital pharmacy customer base and FDA-registered outsourcing facility model.

TypeDirect peer
Description

Pharmedium, owned by Cencora (formerly AmerisourceBergen), is a leading 503B sterile injectable compounder serving U.S. hospitals — the closest direct competitor to QuVa with the added distribution scale of a Big-3 pharmaceutical wholesaler parent.

TypeDirect peer
Description

WG Critical Care is a specialty 503B sterile compounder supplying hospitals with ready-to-administer injectable preparations, competing with QuVa in similar product categories and hospital pharmacy channels.

4Cantrell Drug Company
TypeDirect peer
Description

Cantrell Drug Company is an FDA-registered 503B outsourcing facility providing sterile compounded preparations to hospitals and health systems, overlapping directly with QuVa's compounding portfolio and customer segment.

TypeDirect peer
Description

Olympia Pharmaceuticals operates as a 503B outsourcing compounder serving hospital and clinical customers with sterile injectable preparations, directly competing with QuVa in the outsourced sterile injectable category.

TypeDirect peer
Description

Pentec Health is a specialty sterile compounding provider serving patients and provider organizations with parenteral nutrition and intrathecal therapies, overlapping with QuVa in sterile outsourced preparations for clinical settings.

TypeBroad incumbent
Description

Cencora is one of the Big-3 U.S. pharmaceutical distributors and owns Pharmedium, the closest direct 503B peer of QuVa. As a parent of a direct competitor, Cencora is a broad incumbent whose scale, wholesaler relationships, and capital base exceed QuVa's.

TypeBroad incumbent
Description

B. Braun owns CAPS (Central Admixture Pharmacy Services), a direct 503B competitor to QuVa, and is itself a major manufacturer of IV solutions and sterile injectables. B. Braun is a broad incumbent operating across QuVa's category with deeper balance-sheet resources.

9McKesson
TypeBroad incumbent
Description

McKesson is one of the largest U.S. pharmaceutical distributors and a major player in hospital drug supply, broad-line injectable distribution, and pharmacy services — overlapping with QuVa's hospital-customer base from a wholesaler and services angle.

TypeEmerging player
Description

Omnicell is a leading pharmacy automation and analytics vendor for health systems; its medication-use analytics and diversion-surveillance capabilities overlap meaningfully with QuVa BrightStream's modules, making it a partial-overlap emerging competitor in the pharmacy-software layer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

QuVa Pharma

503B Sterile Injectable Compoundingquvapharma.com

QuVa Pharma is an FDA-registered 503B outsourcing facility that manufactures compounded, ready-to-administer sterile injectable medications for over 3,000 U.S. hospitals, complemented by its BrightStream AI-powered pharmacy analytics platform acquired in 2024.

What QuVa Pharma does

QuVa Pharma is a privately held, FDA-registered 503B outsourcing facility founded in 2015 and headquartered in Sugar Land, Texas. The company manufactures compounded and ready-to-administer sterile injectable medications for hospital pharmacies across all 50 U.S. states, serving over 3,000 hospitals through direct enterprise sales and national group purchasing agreements — most notably with Premier, Inc. Its core portfolio includes low-dose fentanyl syringes, enhanced tamper-evident CADD cassettes, del Nido cardioplegia solution, and a broader ready-to-administer injectable line supported by forward distribution centers and remote direct distribution capabilities.

The company's go-to-market combines direct enterprise field sales to hospital pharmacy leadership with GPO channel partnerships that provide pre-negotiated pricing for member hospitals. In July 2024, QuVa acquired LogicStream Health and rebranded it as Quva BrightStream, adding an AI-powered clinical data and analytics platform comprising six modules — Shortage Navigator, Diversion Surveillance, Supply Advisor, Script Revenue Capture, Contracts Value Maximizer, and Clinical Process Optimizer — that process data from over 350 health-system data sets to deliver predictive shortage management, controlled-substance monitoring, inventory optimization, and revenue retention analytics.

QuVa is backed by Bain Capital (including its January 2024 $15 million equity investment) and previously financed through a $275 million senior debt facility led by Goldman Sachs and Owl Rock in 2021. The business model is dual-track: product revenue from sterile injectable compounding sold through enterprise and GPO channels, plus an emerging SaaS analytics revenue stream through BrightStream that is now embedded into the same Premier GPO procurement vehicle.

QuVa Pharma firmographics

Firmographics
Name
QuVa Pharma
Legal name
QuVa Pharma, Inc.
Website
https://quvapharma.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
QuVa Pharma is an FDA-registered 503B outsourcing facility that manufactures compounded, ready-to-administer sterile injectable medications for over 3,000 U.S. hospitals, complemented by its BrightStream AI-powered pharmacy analytics platform acquired in 2024.
Ownership category
akta.pro rank

QuVa Pharma industry classification

Industry
Product category
503B Sterile Injectable Compounding
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLACAKAI
Medication Inventory, Procurement & Supply Chain (Pharmacy)
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLAIAJAD
Hospital & Health-System Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • 503B sterile compounding
  • Ready-to-administer injectables
  • Hospital pharmacy analytics
  • Drug diversion surveillance
  • Outsourced pharmaceutical manufacturing

Where QuVa Pharma is headquartered

Location

Headquarters

HQ city
Sugar Land
HQ country
United States
HQ region
North America

Offices1 record

Markets served

QuVa Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. 503B Sterile Compounding Services: FDA-registered 503B outsourcing services providing compounded sterile injectable medications to hospitals. Revenue generated through product sales and service agreements with health systems.
  2. AI & Data Analytics Solutions (BrightStream): SaaS-based analytics and software solutions for health-system pharmacy performance improvement, including drug diversion surveillance, shortage management, and revenue optimization.
  3. Ready-to-Administer Portfolio: Pre-packaged, ready-to-administer sterile injectable medications that reduce medication errors and improve pharmacy efficiency.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

QuVa Pharma product offering

Product offering

Core offering

QuVa Pharma is an FDA-registered 503B outsourcing facility that manufactures and distributes compounded, ready-to-administer sterile injectable medications to over 3,000 U.S. hospitals across all 50 states. Through its Quva BrightStream platform (acquired LogicStream Health in July 2024), the company also delivers AI-powered analytics solutions, including drug diversion surveillance, shortage management, supply optimization, and revenue capture for health-system pharmacies. The combined offering pairs physical pharmaceutical manufacturing with data-driven pharmacy intelligence.

Product overview

QuVa Pharma operates as a dual-platform company offering pharmaceutical manufacturing and AI-powered analytics solutions. The core QuVa Pharma platform provides FDA-registered 503B sterile injectable compounding services, delivering ready-to-administer medications to over 3,000 U.S. hospitals across all 50 states. Complementing this is the Quva BrightStream platform (acquired LogicStream Health in July 2024), which offers six AI-powered analytics modules including Shortage Navigator, Diversion Surveillance, Supply Advisor, Script Revenue Capture, Contracts Value Maximizer, and Clinical Process Optimizer. Together, these platforms enable health-system pharmacies to access both essential sterile medications and data-driven insights from over 350 data sets to improve operational performance and patient outcomes.

Differentiator

Problem solved

Functional benefit

Brands

  • Quva BrightStream: AI-powered analytics and data insights platform for health-system pharmacy, offering solutions including shortage navigator, diversion surveillance, supply advisor, script revenue capture, contracts value maximizer, and clinical process optimizer. Formerly known as LogicStream Health.
  • Quva Pharma Ordering Portal
  • BrightStream SaaS Portal

Products and services

  • 503B Sterile Compounding Services FDA-registered 503B outsourcing services providing essential, compounded, ready-to-administer sterile injectable medicines to over 3,000 U.S. hospitals across all 50 states, with industry-first remote direct distribution capabilities and state-of-the-art production facilities.
  • Ready-to-Administer Portfolio Pre-made sterile injectable medications ready for direct patient administration, designed to reduce medication errors and improve pharmacy efficiency in hospital settings.
  • New 503B Product Development Custom sterile injectable product development services for new 503B compounded medications to address unmet hospital needs.
  • del Nido Cardioplegia Solution Sterile cardioplegia solution designed for cardiac surgery, manufactured and distributed as a ready-to-administer compounded sterile injectable.
  • FentaNYL (Low Dose Fentanyl Syringe) Preservative-free sterile injectable fentanyl syringe featuring room temperature storage and a 90-day Beyond Use Date (BUD).
  • CADD Cassettes Sterile injectable cassettes with enhanced tamper-evident cap and packaging to support prevention of leakage and diversion in hospital pharmacy settings.
  • Quva BrightStream Analytics Platform AI-powered analytics and data insights platform (formerly LogicStream Health) that transforms fragmented health-system data from over 350 data sets into actionable intelligence to improve pharmacy performance and patient outcomes, including drug diversion surveillance, shortage management, and supply optimization.

Quantifiable outcome

  • Serves over 3,000 U.S. hospitals
  • +1 more outcomes

Companies that use QuVa Pharma

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

QuVa Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

QuVa Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 1 May 2026QuVa Pharma secured a national group purchasing agreement with Premier, Inc. for its Drug Diversion Software Solutions, effective May 1, 2026. This agreement enhances Premier members' access to QuVa's BrightStream solutions, which help safeguard controlled substances and improve pharmacy compliance and oversight.
  • Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 1 November 2025QuVa Pharma was awarded a national group purchasing agreement for outsourced compounded preparations with Premier, Inc., effective November 1, 2025. This agreement allows Premier members to benefit from pre-negotiated pricing and supports QuVa's role as a provider of sterile injectable compounding services.
  • LogicStream HealthcoreStrategic or Co-development Partner · 25 July 2024QuVa Pharma completed the acquisition of LogicStream Health in July 2024, creating an integrated healthcare platform combining pharmaceutical distribution and AI-powered clinical data solutions. LogicStream Health has been rebranded as BrightStream and provides predictive analytics, drug diversion surveillance, and other pharmacy optimization solutions.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

QuVa Pharma competitors and assessment

Company assessment

Direct peers

  • Central Admixture Pharmacy Services (CAPS): Owned by B. Braun, CAPS is one of the largest 503B sterile compounding outsourcing networks in the U.S., directly competing with QuVa across the same hospital pharmacy customer base and FDA-registered outsourcing facility model.
  • Pharmedium Services: Pharmedium, owned by Cencora (formerly AmerisourceBergen), is a leading 503B sterile injectable compounder serving U.S. hospitals — the closest direct competitor to QuVa with the added distribution scale of a Big-3 pharmaceutical wholesaler parent.
  • WG Critical Care: WG Critical Care is a specialty 503B sterile compounder supplying hospitals with ready-to-administer injectable preparations, competing with QuVa in similar product categories and hospital pharmacy channels.
  • Cantrell Drug Company: Cantrell Drug Company is an FDA-registered 503B outsourcing facility providing sterile compounded preparations to hospitals and health systems, overlapping directly with QuVa's compounding portfolio and customer segment.
  • Olympia Pharmaceuticals: Olympia Pharmaceuticals operates as a 503B outsourcing compounder serving hospital and clinical customers with sterile injectable preparations, directly competing with QuVa in the outsourced sterile injectable category.
  • Pentec Health: Pentec Health is a specialty sterile compounding provider serving patients and provider organizations with parenteral nutrition and intrathecal therapies, overlapping with QuVa in sterile outsourced preparations for clinical settings.

Broad incumbents

  • Cencora (formerly AmerisourceBergen): Cencora is one of the Big-3 U.S. pharmaceutical distributors and owns Pharmedium, the closest direct 503B peer of QuVa. As a parent of a direct competitor, Cencora is a broad incumbent whose scale, wholesaler relationships, and capital base exceed QuVa's.
  • B. Braun Medical: B. Braun owns CAPS (Central Admixture Pharmacy Services), a direct 503B competitor to QuVa, and is itself a major manufacturer of IV solutions and sterile injectables. B. Braun is a broad incumbent operating across QuVa's category with deeper balance-sheet resources.
  • McKesson: McKesson is one of the largest U.S. pharmaceutical distributors and a major player in hospital drug supply, broad-line injectable distribution, and pharmacy services — overlapping with QuVa's hospital-customer base from a wholesaler and services angle.

Emerging players

  • Omnicell: Omnicell is a leading pharmacy automation and analytics vendor for health systems; its medication-use analytics and diversion-surveillance capabilities overlap meaningfully with QuVa BrightStream's modules, making it a partial-overlap emerging competitor in the pharmacy-software layer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

QuVa Pharma social profiles

Digital presence

QuVa Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

QuVa Pharma leadership team

Management profile

Number of profiles

Profiles4 records

QuVa Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

QuVa Pharma funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

QuVa Pharma M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QuVa Pharma

What does QuVa Pharma do?

QuVa Pharma is an FDA-registered 503B outsourcing facility that manufactures and distributes compounded, ready-to-administer sterile injectable medications to over 3,000 U.S. hospitals across all 50 states. Through its Quva BrightStream platform (acquired LogicStream Health in July 2024), the company also delivers AI-powered analytics solutions, including drug diversion surveillance, shortage management, supply optimization, and revenue capture for health-system pharmacies. The combined offering pairs physical pharmaceutical manufacturing with data-driven pharmacy intelligence.

Is QuVa Pharma a public or private company?

QuVa Pharma is a private company. It is classified as private equity controlled and is currently operating.

When was QuVa Pharma founded?

QuVa Pharma was founded in 2015. It employs 1,001 to 5,000 people.

Where is QuVa Pharma based?

QuVa Pharma is headquartered in Sugar Land, United States, in the North America region.

How does QuVa Pharma make money?

Three revenue lines are on record. 503B Sterile Compounding Services are the primary driver. The others are AI & Data Analytics Solutions (BrightStream) and ready-to-Administer Portfolio.

Who are QuVa Pharma's main competitors?

Direct peers on record are Central Admixture Pharmacy Services (CAPS), Pharmedium Services, WG Critical Care, Cantrell Drug Company, Olympia Pharmaceuticals and Pentec Health. Broad incumbents are Cencora (formerly AmerisourceBergen), B. Braun Medical and McKesson. Omnicell is listed as an emerging player.

Does QuVa Pharma have an API?

No public API is recorded for QuVa Pharma.

What industry is QuVa Pharma in?

QuVa Pharma's product category is 503B Sterile Injectable Compounding. Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile), with a secondary code of HLACAKAI, Medication Inventory, Procurement & Supply Chain (Pharmacy). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
njFDA eases compounding rules for preemie nutrition packs as supply shortage loomsThe FDA temporarily eased rules for compounded nutrition products for premature newborns after two CAPS facilities announced permanent closures. The policy allows more pharmacies to compound the product without a patient-specific prescription and remains in effect for 180 days. QuVa Pharma acquired CAPS' TPN line and expects to begin production later this year.AL.comFDA eases compounding rules for preemie nutrition packs as supply shortage loomsThe FDA temporarily eased rules for compounded nutrition products for premature newborns after two outsourcing facilities announced permanent closures. The policy allows more pharmacies to compound the product, including without a patient-specific prescription, and remains in effect for 180 days. QuVa Pharma acquired a CAPS portfolio and expects to begin production later this year.Pulse 2.0Quva Acquires CAPS 503B Sterile Compounding Product PortfolioQuva Pharma acquired a portfolio of essential medications from CAPS after CAPS exited the 503B sterile compounding business. Financial terms were not disclosed, and Quva expects phased product introductions starting later in 2026. The portfolio includes Cardioplegia, Total Parenteral Nutrition, and Heparin.MorningstarCentral Admixture Pharmacy Services Announces Sale of 503B Product Portfolio to Quva PharmaQuva Pharma acquired Central Admixture Pharmacy Services' 503B sterile compounding product portfolio after CAPS exited the business. Quva expects to introduce selected products in phases later in 2026 and expand over six months. The acquisition aims to maintain supply of critical medications to U.S. hospitals.MorningstarQuva acquires Central Admixture Pharmacy Services' 503B Product PortfolioQuva acquired Central Admixture Pharmacy Services' 503B sterile compounding portfolio after CAPS exited the business. Quva expects to introduce selected products in phases later in 2026 and expand over six months. The acquisition aims to maintain supply of critical medications like Cardioplegia and Heparin.openPR.comU.S. 503B Compounding Pharmacies Market is Going to Booming Growth 2026-2033 | Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa PharmaCoherent Market Insights published a market research report forecasting the U.S. 503B compounding pharmacies market to grow from $985.6 million in 2022 at a CAGR of 7.6% through 2030. The study analyzes competitive dynamics and provides strategic insights for key industry participants including Central Admixture Pharmacy Services, Nephron Pharmaceuticals, and QuVa Pharma. This analysis serves as a tool for investors and business leaders to identify growth avenues and optimize market entry strategies.PR NewswireQuva awarded National Drug Diversion Software Solutions agreement with Premier, Inc.QuVa Pharma, Inc has secured a national group purchasing agreement with Premier, Inc for its Drug Diversion Software Solutions, starting May 1, 2026. The agreement enhances Premier members' access to QuVa's BrightStream solutions, which help safeguard controlled substances and improve pharmacy compliance and oversight.PR NewswireQuva Awarded National Outsourced Compounded Preparations Agreement with Premier, Inc.QuVa Pharma, Inc was awarded a national group purchasing agreement for outsourced compounded preparations with Premier, Inc, effective November 1, 2025. This agreement allows Premier members to benefit from pre-negotiated pricing and supports QuVa's role as a provider of sterile injectable compounding services.openPR.comU.S. 503B Compounding Pharmacies Market 2025-2032: Growth Overview, Facts & Figures, Segmentation, Future Trends, and Historical Analysis | Nephron Pharmaceuticals Corporation • QuVa Pharma • OlympiaThe U.S. 503B compounding pharmacies market is projected to grow from USD 985.6 million in 2025 to USD 1,766 million by 2032, a CAGR of 7.6%. Key players include Central Admixture Pharmacy Services, Nephron Pharmaceuticals, and QuVa Pharma, with segmentation by product type, application, and end user.Coherent Market InsightsU.S. Injectable Compounding Pharmacy Market Forecast, 2033This report provides a comprehensive market analysis and forecast for the U.S. injectable compounding pharmacy industry, projecting the market to grow from USD 1,745.4 million in 2026 to USD 2,858.2 million by 2033, representing a compound annual growth rate of 7.3%. Key growth drivers include the increasing prevalence of chronic diseases in the U.S. and advancements in drug delivery methods, while product recalls pose a significant restraint to market expansion. The market is segmented by molecule type, packaging type (with prefilled syringes leading), and pharmacy type (503A and 503B pharmacies), and features multiple key players including Central Admixture Pharmacy Services, Nephron Pharmaceuticals, QuVa Pharma, and others.